28232-63-5

Basic information

• Product Name: 3-Bromo-5-phenoxypyridine
• Synonyms: 3-Bromo-5-phenoxypyridine;5-broMo-3-phenoxy-pyridine;Pyridine, 3-broMo-5-phenoxy-
• CAS NO: 28232-63-5
• Molecular Formula: C₁₁H₈BrNO
• Molecular Weight: 250.094
• EINECS: 604-604-1
• Mol File: 28232-63-5.mol

Chemical Properties

• Boiling Point: 311.561 °C at 760 mmHg
• Flash Point: 142.227 °C
• Appearance: /
• Density: 1.476 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 1.84±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-5-phenoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-phenoxypyridine(28232-63-5)
• EPA Substance Registry System: 3-Bromo-5-phenoxypyridine(28232-63-5)

Safety Data

• Hazardous Substances Data: 28232-63-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-5-phenoxypyridine is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-5-phenoxypyridine serves as a precursor for the production of agrochemicals, contributing to the creation of effective pesticides and other agricultural chemicals.
Used in Organic Synthesis:
3-Bromo-5-phenoxypyridine is utilized as a building block in organic synthesis for the preparation of a wide range of fine chemicals, including specialty chemicals and intermediates for various applications.
Used as a Reagent in Chemical Reactions:
3-Bromo-5-phenoxypyridine also functions as a reagent, facilitating the introduction of the 3-bromo-5-phenoxypyridine moiety into target molecules, enhancing the structural diversity and functional groups in synthesized products.
Used in Material Science:
3-Bromo-5-phenoxypyridine has potential applications in material science, where it may contribute to the development of new materials with unique properties, such as光电材料 (photoelectric materials), 磁性材料 (magnetic materials), and 高分子材料 (polymeric materials).
Used as a Precursor for Synthesis of Functionalized Heterocyclic Compounds:
Lastly, 3-Bromo-5-phenoxypyridine is employed as a precursor in the synthesis of functionalized heterocyclic compounds, which are important in various chemical and pharmaceutical applications due to their diverse and often biologically active structures.

Upstream product

• 625-92-3 3,5-dibromopyridine 
• 108-95-2 phenol 
• 212332-40-6 3-bromo-5-isopropoxypyridine 

Downstream Products

• 646055-72-3 1-benzyl-7-(5-phenoxy-3-pyridyl)-1,7-diazaspiro[4.4]nonane 
• 212332-39-3 (E)-4-[3-(5-phenoxypyridin)yl]-3-buten-1-ol 
• 910649-39-7 3-methoxy-5-phenoxypyridine 
• 910649-40-0 5-phenoxy-3-pyridinol 

Relevant articles and documents

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Structure-activity studies of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes: A novel class of highly potent nicotinic receptor ligands

The potential for nicotinic ligands with affinity for the α4β2 or α7 subtypes to treat such diverse diseases as nicotine addiction, neuropathic pain, and neurodegenerative and cognitive disorders has been exhibited clinically for several compounds while p

BICYCLIC DIAMINES AS NICOTINIC RECEPTOR AGONISTS

Compounds; pharmaceutically acceptable salts thereof; and stereoisomers of the compound of Formula I and pharmaceutically acceptable salts thereof; are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Cor

THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION

Compounds, compositions and methods for treating drug addiction, nicotine addiction, and/or obesity are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteraryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds are effective at inhibiting dopamine production and/or secretion, and accordingly are effective at inhibiting the physiological "reward" process that is associated with ingestion of nicotine and/or illicit drugs. The compounds and compositions can be administered in effective amounts to inhibit dopamine release, wihout resulting in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME

A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar-B- group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R5, R6, R7, and R8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar-B'- group (B' is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an -NR4- group (R4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R4' is hydrogen atom, or a group represented by the aforementioned formula (a) (R3" and R4" represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl subst